TCR2 Therapeutics

Cell and Gene
Share

TCR² is a clinical-stage immunotherapy company developing a new generation of T cell therapies for patients suffering from cancer.

Our proprietary TRuC™ (TCR Fusion Construct) T cells harness the natural T cell receptor complex to recognize and kill cancer cells using the full power of T cell signaling pathways independent of HLA.  

Stevenage Bioscience Catalyst is the UK's leading open innovation campus with a focus on therapeutics.

Learn more

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.